This study aims to estimate the lower, middle, and upper bounds of potential demand for psilocybin-assisted therapy (PSIL-AT) for major depressive disorder (MDD) and treatment-resistant depression (TRD) in the United States. We calculated potential PSIL-AT demand for MDD and TRD by estimating the number of U.S. patients with MDD, identifying those in treatme...
Abstract Objectives The first line for symptom management of attention deficit hyperactivity disorder (ADHD) is a class of medications that act on dopamine and noradrenaline receptors, which leads to symptom reduction at the cost of significant side effects. These side effects have led to community searching for alternative methods that manage ADHD symptoms ...
Introduction:Psilocybin-assisted therapy (PAT) has gained traction in palliative care as a treatment for existential distress in the last decade. Patients with brain cancer have been excluded from studies, yet they stand to benefit as much as other patients with cancer-related psychological distress. Case description:In this report, we discuss the case of a ...
Psilosibin, klasik bir serotonerjik psikedelik madde olup, depresyon, anksiyete, travma sonrası stres bozukluğu, obsesif kompulsif bozukluk, yeme bozuklukları ve bağımlılık gibi ruhsal bozuklukların tedavisinde umut vaat etmektedir. Bu derleme, mevcut literatürü analiz ederek, psilosibinin terapötik etkilerini, olası mekanizmalarını ve klinik kullanımına dai...
This work utilized fMRI to assess the influence of the psychedelics, Psilocybin, a serotonergic agonist, and Salvinorin-A, a kappa-opioid receptor (KOR) agonist, on functional connectivity (FC) in non-human primates. We used a seed-based FC analysis, probing regions of interest associated with psychedelic hallucinogens. Our findings highlight the overlapping...
Depression is a global public health challenge that represents the world's largest cause of disability, especially in the context of traditional treatments. One potential solution being explored is psilocybin assisted psychotherapy (PAP) which shows promise for treating depression. A recent study by Rosenblat et al. explores the use of psilocybin in clinical...
Background: Research investigating high-dose, high-support psilocybin-assisted therapy reports significant psychological benefits, increased consciousness, and an enhanced socio-cognitive niche, resulting in empathy, connection, creativity, and overall well-being. These qualities lend themselves well to the bonding, emotional regulation, and attachment requi...
Abstract Effective interventions for neuropsychiatric disorders may work by rebalancing the brain’s functional hierarchical organization. Here we directly investigated the effects of two different serotonergic pharmacological interventions on functional brain hierarchy in major depressive disorder in a two-arm double-blind phase II randomized controlled tria...
As a proposed mediator between stigma-related stressors and negative mental health outcomes, HIV-related shame has been predictive of increased rates of substance use and difficulties adhering to antiretroviral treatment among people with HIV. These downstream manifestations have ultimately impeded progress toward national goals to End the HIV Epidemic, in p...
Post-Traumatic Stress Disorder (PTSD) is a debilitating mental health condition that can occur after experiencing or witnessing a traumatic event. The impact of PTSD extends beyond the individual, affecting families, communities, and society as a whole. This study aims to investigate the potential of psilocybin as a treatment for PTSD. Psilocybin, after bein...
In the past few years, psilocybin, a psychedelic compound found in "magic mushrooms" (psilocybin mushrooms), has undergone decriminalization in numerous cities across the US and has been legalized in Oregon and Colorado. Proponents of psilocybin decriminalization have emphasized its therapeutic potential in treating mental health disorders. Furthermore, psil...
BACKGROUND: Major depressive disorder (MDD) is a leading cause of disability worldwide across domains of health and cognition, affecting overall quality of life. Approximately one third of individuals with depression do not fully respond to treatments (e.g., conventional antidepressants, psychotherapy) and alternative strategies are needed. Recent early phas...
Several trials of psilocybin for symptoms of depression have shown encouraging findings, as have a number of systematic reviews and meta-analyses. However, several of the reviews have included nonrandomized trials and studies in which psilocybin was used in conjunction with psychotherapeutic interventions, making it difficult to isolate psilocybin's effects...
Background: Hypertension is a major source of morbidity and mortality worldwide, particularly for racial and ethnic minorities who face higher rates of hypertension and worse health-related outcomes. Recent research has reported on protective associations between classic psychedelics and hypertension; however, there is a need to explore how race and ethnicit...
Introduction: In Colorado, both cannabis and psilocybin are legal and becoming more commonly used. However, there is almost no research detailing the public health concerns regarding negative outcomes (e.g., dependence) of cannabis and psilocybin co-use and motives that may perpetuate these negative outcomes (e.g., coping, boredom). Methods: Using data from ...
